FEATURES OF DEVELOPMENT OF NEUROENDOCRINE DYSFUNCTION IN PATIENTS WITH SCHIZOPHRENIA IN OUTPATIENT PRACTICE (NATURALISTIC STUDY)
- Autores: Gorobets L.N1, Bulanov V.S1, Litvinov A.V1
-
Afiliações:
- Moscow SRI of Psychiatry - Branch of FSBI FMRCPN n.a. V.P. Serbsky of RMH
- Edição: Nº 4S (2016)
- Páginas: 41-45
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289725
- ID: 289725
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article discusses data on the frequency of incidence of neuroendocrine dysfunction (NED) in patients with paranoid schizophrenia during long-term antipsychotic therapy in outpatient practice in the comparative aspect. Generally, NED has formed in 94.3% of patients. Frequency of development of NED in patients varied from 90.5 to 100% depending on therapy options. NED in patients with paranoid schizophrenia with appointment of two or more antipsychotics or combination of antidepressant and antipsychotic compared with first and second generation antipsychotics used as monotherapy are formed significantly more often (p<0.01). Average prolactin levels were significantly higher (p<0.01) in women with all variants of therapy and significantly higher (p<0.01) than those against the background of treatment with second-generation antipsychotics, regardless of gender. In addition, the spectrum of clinical manifestations of syndrome of neuroleptic-induced hyperprolactinemia in women was significantly greater compared to male patients.
Texto integral
Sobre autores
L. Gorobets
Moscow SRI of Psychiatry - Branch of FSBI FMRCPN n.a. V.P. Serbsky of RMH
Email: gorobetsln@mail.ru
MD, Prof., Head of the Department of Psychiatric Endocrinology Moscow
V. Bulanov
Moscow SRI of Psychiatry - Branch of FSBI FMRCPN n.a. V.P. Serbsky of RMHMoscow
A. Litvinov
Moscow SRI of Psychiatry - Branch of FSBI FMRCPN n.a. V.P. Serbsky of RMHMoscow
Bibliografia
- Аведисова А.С., Ахапкин Р.В. Проблемы клинической оценки переносимости терапии психотропными препаратами. Психиатрия и психофармакотерапия. Журнал им. П.Б. Ганнушкина. 2005;7(1):17-20.
- Ванина Е., Подольская А., Седки К. и др. Изменения веса тела, связанные с психофармакотерапией. Метаболические побочные эффекты и осложнения психофармакотерапии (Прил. к журналу «Социальная и клиническая психиатрия»). М., 2003. С. 2-8.
- Горобец Л.Н. Нейроэндокринные дисфункции и нейролептическая терапия. М., 2007.
- Горобец Л.Н. Нейроэндокринные дисфункции у больных шизофренией и шизоаффективным расстройством, развивающиеся в процессе длительной терапии атипичными антипсихотиками (эпидемиология, клиника, динамика). Российский психиатрический журнал. 2008;4:79-85.
- Мазо Г.Э. Перспективы развития эндокринологической психиатрии. Сборник научных трудов «Современные достижения в диагностике и лечении эндогенных расстройств». СПб., 2008. С. 210-24.
- Мосолов С.Н. Современный этап развития психофармакотерапии. Сборник «Новые достижения в терапии психических заболеваний». М., 2002. С. 21.
- Мосолов С.Н., Кабанов С.О. Метаболические нарушения при антипсихотической терапии. Социальная и клиническая психиатрия. 2003;13(2):162-72.
- Allison D.B., Mentor J.M., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156(11):1686-96.
- Fleischhacker W.W, Hofer A., Hummer M. Managing Schizophrenia: The Compliance Challenge. 2nded. 2008. Р. 50.
- Green J.K., Patel J.K., Goisman R.M., Allison D.B., Blackburn G. Weight Gain From Novel Antypsychotic Drugs: Need For Action. Gen. Hosp. Psychiatry. 2000;22:224-35.
- Groleger U., Novak-Grubic V. Gender, psychosis and psychotropic drugs: differences and similarities. Psychiatr. Danub. 2010; 22(2):338-42.
- Grunder G., Wetzel H., Schlosser R. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol. Psychiatry. 1999;45(1):89-97.
- Haack S., Seeringer A., Thürmann P.A., Becker T., Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009;10(9):1511-26.
- Haupt D.W. Differential metabolic effects of antipsychotic treatments. Eur. Neuropsychopharmacol. 2006;16(Suppl. 3) S149-55.
- Kinon B.J., Gilmore J.A., Liu Н., Halbreich U.M. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28;69-82.
- Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 2000;401:3-38.
- Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics - a review. Hum. Psychopharmacol. Clin. Exp. 2010;25;281-97.
- Perkins D.O. Prolactin- and Endocrine-Related Disorders in Schizophrenia / Medical Illnes and Schizofrenia (ed. by Meyer J.M. and Nasrallah H.A.). Am. Psychiatr. Publ. Washington, London. 2003. Р 215-32.
- Peuskens J. Prolactin in schizophrenia a literature review. Clear perspectives. 1997;1(3). Management issues in schizophrenia. 42 p.
- Smith S. Gender differences in antipsychotic prescribing. Int. Rev. Psychiatry. 2010;22(5):472-84.
- Stanton J.M. Weight gain associated with neuroleptic medication: a review. Schizoph. Bull. 1995;21:463-72.
- Sussmun N. Weight gain and glucose regulation during antipsychotic drug treatment. J. Clin. Psychiatry. 2001;62(Suppl 23):3-4.
Arquivos suplementares
